A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]
Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol. 2018;12:1921–1929.On page 1927, “Safety and tolerability assessments” section, third paragraph, first sentence should read from “Fifteen subjects exited the study due to AE...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-01-01
|
| Series: | Clinical Ophthalmology |
| Online Access: | https://www.dovepress.com/corrigendum2-a-phase-iiiii-randomized-double-masked-vehicle-contr-peer-reviewed-article-OPTH |
| Summary: | Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol. 2018;12:1921–1929.On page 1927, “Safety and tolerability assessments” section, third paragraph, first sentence should read from “Fifteen subjects exited the study due to AEs: 5 subjects (3.3%) in the OTX-101 0.09% group, 4 subjects (2.6%) in the OTX-101 0.09% group, and 6 subjects (3.9%) in the vehicle group.” to “Fifteen subjects exited the study due to AEs: 5 subjects (3.3%) in the OTX-101 0.09% group, 4 subjects (2.6%) in the OTX-101 0.05% group, and 6 subjects (3.9%) in the vehicle group.”Read the original articlePrevious corrigendum has been published |
|---|---|
| ISSN: | 1177-5483 |